Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Papillomavirus Infections 1Carcinoma in Situ 1

Interventions

Cyclophosphamide 637Bevacizumab 552Paclitaxel 533Carboplatin 531Cisplatin 478pembrolizumab 452Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 371Dexamethasone 349Doxorubicin 325Nivolumab 307Fluorouracil 286Capecitabine 260Prednisone 243Oxaliplatin 242Erlotinib Hydrochloride 242Etoposide 239Lenalidomide 231Cytarabine 230Trastuzumab 227Pemetrexed 219fludarabine phosphate 207Vincristine 207Leucovorin 207Cetuximab 207Filgrastim 204Bortezomib 191Methotrexate 181

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Has results × Codeine × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡